ATTR-cardiac amyloidosis (ATTR-CM) was assessed in a clinical study.
Proven results
with Attruby
Actor portrayals.
Understanding how Attruby was studied
ATTR-cardiac amyloidosis (ATTR-CM) was assessed in a clinical study.
Attruby is proven to impact:
-
Survival
-
Hospitalization due to heart issues
-
Health-related quality of life
See Results
Exploring the study
-
611
People participated
This study is one of the largest for
ATTR-CM -
77
Average age
The average age of people in the study
with wild-typeor hereditary
ATTR-CM
was 77 years old -
409
People took Attruby
Out of 611 people, 409 took Attruby and 202 received placebo -
30
Months
The study lasted for 30 months -
90%
Were male
10%
Were female
- 10% had hereditary ATTR-CM
- 58% had a history of atrial fibrillation
- 19% had a permanent pacemaker
How well Attruby worked was calculated by taking specific measures at the beginning and comparing them with those same measures at the end of the study.
Primary measures, which helped determine how well Attruby worked over the 30-month study, included a combined measure of:
-
Survival
-
Hospital visits due to heart issues
Additional assessments included:
-
Blood test measurements
; when your
heart isn’t working properly, your body has a
biochemical response which can be assessedThe most common tests are:
-
TTR or prealbumin blood test
- NT-proBNP
-
TTR or prealbumin blood test
-
Health-related quality of life, which was
measured using a questionnaire specifically
designed for people who have cardiomyopathyQuality of life was measured using a questionnaire known
as the Kansas City Cardiomyopathy Questionnaire (KCCQ).
It consists of 23 questions that help your doctor get a clearer picture of your quality of life by reviewing the frequency and burden of symptoms, and how you are doing physically
and emotionally. -
Walking distance in 6 minutes, which measures heart function and exercise capacity
How far a person could walk at the beginning of the study
was compared with how far they could walk after 30 months
of treatment.
*ATTR-cardiac amyloidosis is also known as transthyretin-mediated cardiomyopathy (ATTR-CM).
Next: Results